- Home
- PHAR vs ASM Comparison
PHAR vs ASM Comparison
Compare PHAR & ASM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ASM
- Stock Information
- Founded
- PHAR 1988
- ASM 1968
- Country
- PHAR Netherlands
- ASM Canada
- Employees
- PHAR N/A
- ASM N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ASM Metal Mining
- Sector
- PHAR Health Care
- ASM Basic Materials
- Exchange
- PHAR Nasdaq
- ASM Nasdaq
- Market Cap
- PHAR 707.9M
- ASM 612.8M
- IPO Year
- PHAR N/A
- ASM N/A
- Fundamental
- Price
- PHAR $10.96
- ASM $3.23
- Analyst Decision
- PHAR Strong Buy
- ASM Buy
- Analyst Count
- PHAR 3
- ASM 2
- Target Price
- PHAR $30.00
- ASM $3.15
- AVG Volume (30 Days)
- PHAR 5.3K
- ASM 5.5M
- Earning Date
- PHAR 07-31-2025
- ASM 08-13-2025
- Dividend Yield
- PHAR N/A
- ASM N/A
- EPS Growth
- PHAR N/A
- ASM 715.13
- EPS
- PHAR N/A
- ASM 0.10
- Revenue
- PHAR $339,836,000.00
- ASM $72,621,000.00
- Revenue This Year
- PHAR $12.88
- ASM $31.71
- Revenue Next Year
- PHAR $8.54
- ASM $28.15
- P/E Ratio
- PHAR N/A
- ASM $35.51
- Revenue Growth
- PHAR 22.44
- ASM 56.32
- 52 Week Low
- PHAR $6.73
- ASM $0.83
- 52 Week High
- PHAR $12.61
- ASM $4.41
- Technical
- Relative Strength Index (RSI)
- PHAR 58.06
- ASM 40.35
- Support Level
- PHAR $9.54
- ASM $3.10
- Resistance Level
- PHAR $10.46
- ASM $4.41
- Average True Range (ATR)
- PHAR 0.37
- ASM 0.22
- MACD
- PHAR 0.10
- ASM -0.09
- Stochastic Oscillator
- PHAR 81.20
- ASM 10.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.